Skip to main content

Dose-Finding Methods for Two-Agent Combination Phase I Trials

  • Chapter
  • First Online:
Developments in Statistical Evaluation of Clinical Trials
  • 1943 Accesses

Abstract

In this chapter, we discuss the toxicity-based dose-finding methods for two-agent combinations in phase I oncology trials. The model-based approaches, such as the continual reassessment method (CRM), have been gradually applied to single-agent trials to determine the maximum tolerated dose (MTD). By contrast, the rule-based approaches have commonly been applied to two-agent combination trials, probably due to the absence of well-understood model-based methods for two-agent combination trials. In developing a dose-finding method for two-agent combination trials, we require a reasonable model that can adequately capture joint toxicity probabilities for two agents, taking into consideration of possible interactions of the two agents on toxicity probability (such as synergistic or antagonistic effects). We provide an overview of two useful dose-finding approaches based on Bayesian copula-type models and partial orderings across dose levels for two-agent combination trials. We also supply examples of successful software implementations and discuss the operating characteristics of these approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cheung, Y. K.: Dose Finding by the Continual Reassessment Method. New York, Chapman & Hall (2011)

    Google Scholar 

  2. Conaway, M. R., Dunbar, S., Peddada, S. D.: Designs for single- or multiple-agent phase I trials. Biometrics 60, 661–669 (2004)

    Google Scholar 

  3. Copas, J. B.: Regression, prediction and shrinkage. Journal of the Royal Statistical Society Series B 45, 311–354 (1983)

    Google Scholar 

  4. Copas, J. B.: Using regression models for prediction: Shrinkage and regression to the mean. Statistical Methods in Medical Research 6, 167–183 (1997)

    Google Scholar 

  5. Gasparini, M., Bailey, S., Neuenschwander, B.: Correspondence: Bayesian dose finding in oncology for drug combinations by copula regression. Journal of the Royal Statistical Society Series C 59, 543–546 (2010)

    Google Scholar 

  6. Goodman, S. N., Zahurak, M. L., Piantadosi, S.: Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 14, 1149–1161 (1995)

    Google Scholar 

  7. Hirakawa, A., Hamada, C., Matsui, S.: A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials. Statistics in Medicine 32, 4515–4525 (2013)

    Google Scholar 

  8. Lee, S. M., Cheung, Y. K.: Model calibration in the continual reassessment method. Clinical Trials 6, 227–238 (2009)

    Google Scholar 

  9. Lokich, J.: Phase I clinical trial of weekly combined topotecan and irinotecan. American Journal of Clinical Oncology 24, 336–40 (2001)

    Google Scholar 

  10. Nelsen, R. B.: An Introduction to Copulas, 2nd edn. New York, Springer (2006)

    Google Scholar 

  11. O’Quigley, J., Pepe, M., Fisher, L.: Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 46, 33–48 (1990).

    Google Scholar 

  12. O’Quigley, J., Shen, L. Z.: Continual reassessment method: A likelihood approach. Biometrics 52, 673–684 (1996)

    Google Scholar 

  13. Robertson, T., Wright, F. T., Dykstra, R. L., Dykstra, R.: Order Restricted Statistical Inference. New York, John Wiley & Sons (1988)

    Google Scholar 

  14. Thall, P. F., Millikan, R. E., Mueller, P., Lee, S. J.: Dose finding with two agents in phase I oncology trials. Biometrics 59, 487–496 (2003)

    Google Scholar 

  15. Wages, N. A., Conaway, M. R., O’Quigley, J.: Continual reassessment method for partial ordering. Biometrics 67, 1555–1563 (2011a)

    Google Scholar 

  16. Wages, N. A., Conaway, M. R., O’Quigley, J.: Dose-finding design for multi-drug combinations. Clinical Trials 8, 380–389 (2011b)

    Google Scholar 

  17. Wang, K., Ivanova, A.: Two-dimensional dose finding in discrete dose space. Biometrics 61, 217–222 (2005)

    Google Scholar 

  18. Yin, G., Yuan, Y.: A latent contingency table approach to dose finding for combinations of two agents. Biometrics 65, 866–875 (2009a)

    Google Scholar 

  19. Yin, G., Yuan, Y.: Bayesian dose finding in oncology for drug combinations by copula regression. Journal of the Royal Statistical Society Series C 58, 211–224 (2009b)

    Google Scholar 

Download references

Acknowledgements

This work was partially supported by JSPS KAKENHI Grant Number 25730015 (Grant-in-Aid for Young Scientists B).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Akihiro Hirakawa .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hirakawa, A., Matsui, S. (2014). Dose-Finding Methods for Two-Agent Combination Phase I Trials. In: van Montfort, K., Oud, J., Ghidey, W. (eds) Developments in Statistical Evaluation of Clinical Trials. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55345-5_15

Download citation

Publish with us

Policies and ethics